Prospective Evaluation of Drug-Eluting Stents in Routine Clinical Practice (ASAN PCI Registry)

This study has been completed.
Information provided by (Responsible Party):
Seung-Jung Park, Asan Medical Center Identifier:
First received: February 8, 2013
Last updated: December 8, 2014
Last verified: December 2014
The objective of this study is to evaluate effectiveness and safety of drug-eluting stent implantation in the "real world" daily practice.

Coronary Artery Disease

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 1 Year
Official Title: Prospective Evaluation of Drug-Eluting Stents in Routine Clinical Practice

Resource links provided by NLM:

Further study details as provided by Asan Medical Center:

Primary Outcome Measures:
  • Major Adverse Cardiac Event [ Time Frame: 1year ] [ Designated as safety issue: Yes ]
    Death from any causes, myocardial infarction or any repeat revascularization

Secondary Outcome Measures:
  • all cause Death [ Time Frame: 1year ] [ Designated as safety issue: Yes ]
  • Myocardial Infarction [ Time Frame: 1year ] [ Designated as safety issue: Yes ]
  • The composite of Death or myocardial infarction [ Time Frame: 1year ] [ Designated as safety issue: Yes ]
  • Any repeat revascularization [ Time Frame: 1year ] [ Designated as safety issue: No ]
  • Target vessel revascularization [ Time Frame: 1year ] [ Designated as safety issue: No ]
  • Target lesion revascularization [ Time Frame: 1year ] [ Designated as safety issue: No ]
  • New lesion revascularization [ Time Frame: 1year ] [ Designated as safety issue: No ]
  • Stent thrombosis by Academic Research Consortium criteria [ Time Frame: 1year ] [ Designated as safety issue: Yes ]

Enrollment: 5097
Study Start Date: January 2003
Study Completion Date: October 2013
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Drug eluting stent
Patients who receiving drug eluting stents


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
consecutive patients amenable to percutaneous coronary intervention with drug eluting stents

Inclusion Criteria:

  • coronary disease amenable to percutaneous coronary intervention (PCI)
  • no clinical and lesion limitations

Exclusion Criteria:

  • patients with a mixture of several drug eluting stents
  • terminal illness with life expectancy less than 1 year
  • patients with cardiogenic shock
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01788592

Korea, Republic of
Asan Medical Center
Seoul, Korea, Republic of
Sponsors and Collaborators
Seung-Jung Park
Principal Investigator: Seung-Jung Park, MD, PhD Asan Medical Center
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Seung-Jung Park, MD,PhD, Chairman,Heart Institute, Asan Medical Center,University of Ulsan,College of Medicine, Asan Medical Center Identifier: NCT01788592     History of Changes
Other Study ID Numbers: AMCCV2013-02 
Study First Received: February 8, 2013
Last Updated: December 8, 2014
Health Authority: Korea: Institutional Review Board

Keywords provided by Asan Medical Center:
coronary artery disease
drug eluting stent

Additional relevant MeSH terms:
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Arterial Occlusive Diseases
Cardiovascular Diseases
Heart Diseases
Vascular Diseases processed this record on May 24, 2016